Clinical trials: Chronic Lymphocytic Leukemia (CLL) - Refractory
- Condition Chronic Lymphocytic Leukemia (CLL) - Refractory
- Funder type Industry (pharma, biotech, devices)
Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute
MK0457 in Patients With Leukemia (0457-003)
In this study participants with relapsed/refractory leukemia will be given MK-0457 in sequential cohorts and with varying treatment duration to determine the maximum tolerated dose (MTD) for MK-0457.
- Conditions
- Chronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute, Myelodysplastic Syndromes, Myelogenous Leukemia, Chronic
- Trial name
- NCT00111683
- Testing
- MK0457
- Volunteers
- 28 people
- Sponsor
- Merck Sharp & Dohme LLC